March 27, 2018
JCR Chairman and President Shin Ashida Japanese biotech JCR Pharmaceuticals is aiming to snatch a large slice of the global lysosomal storage disease market, worth 900 billion yen with existing drugs, by rolling out new medicines that harness the company’s...read more